These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 27960087)

  • 21. Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.
    Beg MS; Huang X; Silvers MA; Gerber DE; Bolluyt J; Sarode V; Fattah F; Deberardinis RJ; Merritt ME; Xie XJ; Leff R; Laheru D; Boothman DA
    J Surg Oncol; 2017 Jul; 116(1):83-88. PubMed ID: 28346693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells.
    Kung HN; Weng TY; Liu YL; Lu KS; Chau YP
    PLoS One; 2014; 9(2):e88122. PubMed ID: 24505400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. X-ray repair cross-complementing protein 1 (XRCC1) loss promotes β-lapachone -induced apoptosis in pancreatic cancer cells.
    Zheng Y; Zhang H; Guo Y; Chen Y; Chen H; Liu Y
    BMC Cancer; 2021 Nov; 21(1):1234. PubMed ID: 34789190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
    Wu X; Li X; Li Z; Yu Y; You Q; Zhang X
    J Med Chem; 2018 Dec; 61(24):11280-11297. PubMed ID: 30508483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.
    Reinicke KE; Bey EA; Bentle MS; Pink JJ; Ingalls ST; Hoppel CL; Misico RI; Arzac GM; Burton G; Bornmann WG; Sutton D; Gao J; Boothman DA
    Clin Cancer Res; 2005 Apr; 11(8):3055-64. PubMed ID: 15837761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.
    Parsels LA; Karnak D; Parsels JD; Zhang Q; Vélez-Padilla J; Reichert ZR; Wahl DR; Maybaum J; O'Connor MJ; Lawrence TS; Morgan MA
    Mol Cancer Res; 2018 Feb; 16(2):222-232. PubMed ID: 29133592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone.
    Bentle MS; Reinicke KE; Dong Y; Bey EA; Boothman DA
    Cancer Res; 2007 Jul; 67(14):6936-45. PubMed ID: 17638905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
    Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.
    Kivlin CM; Watson KL; Al Sannaa GA; Belousov R; Ingram DR; Huang KL; May CD; Bolshakov S; Landers SM; Kalam AA; Slopis JM; McCutcheon IE; Pollock RE; Lev D; Lazar AJ; Torres KE
    Cancer Biol Ther; 2016; 17(2):129-38. PubMed ID: 26650448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combinative effects of β-Lapachone and APO866 on pancreatic cancer cell death through reactive oxygen species production and PARP-1 activation.
    Breton CS; Aubry D; Ginet V; Puyal J; Heulot M; Widmann C; Duchosal MA; Nahimana A
    Biochimie; 2015 Sep; 116():141-53. PubMed ID: 26188110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Albumin binding revitalizes NQO1 bioactivatable drugs as novel therapeutics for pancreatic cancer.
    Dou L; Liu H; Wang K; Liu J; Liu L; Ye J; Wang R; Deng H; Qian F
    J Control Release; 2022 Sep; 349():876-889. PubMed ID: 35907592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic Effect of β-Lapachone and Aminooxyacetic Acid on Central Metabolism in Breast Cancer.
    Chang MC; Mahar R; McLeod MA; Giacalone AG; Huang X; Boothman DA; Merritt ME
    Nutrients; 2022 Jul; 14(15):. PubMed ID: 35893874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
    Cheng H; Zhang Z; Borczuk A; Powell CA; Balajee AS; Lieberman HB; Halmos B
    Carcinogenesis; 2013 Apr; 34(4):739-49. PubMed ID: 23275151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone.
    Chakrabarti G; Moore ZR; Luo X; Ilcheva M; Ali A; Padanad M; Zhou Y; Xie Y; Burma S; Scaglioni PP; Cantley LC; DeBerardinis RJ; Kimmelman AC; Lyssiotis CA; Boothman DA
    Cancer Metab; 2015; 3():12. PubMed ID: 26462257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
    Wang W; Duan B; Zeng L
    Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic enhancement of antitumor effect of β-Lapachone by photodynamic induction of quinone oxidoreductase (NQO1).
    Lamberti MJ; Vittar NB; da Silva Fde C; Ferreira VF; Rivarola VA
    Phytomedicine; 2013 Aug; 20(11):1007-12. PubMed ID: 23746950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of poly(ADP-ribose) polymerase activation attenuates beta-lapachone-induced necrotic cell death in human osteosarcoma cells.
    Liu TJ; Lin SY; Chau YP
    Toxicol Appl Pharmacol; 2002 Jul; 182(2):116-25. PubMed ID: 12140175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
    Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
    Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of talaporfin photodynamic therapy and Poly (ADP-Ribose) polymerase (PARP) inhibitor in gastric cancer.
    Tanaka M; Sasaki M; Suzuki T; Nishie H; Kataoka H
    Biochem Biophys Res Commun; 2021 Feb; 539():1-7. PubMed ID: 33388624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.